Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Syngene"

63 News Found

Biosimilars performance below expectations for Biocon : ICICI Direct
Biotech | May 03, 2021

Biosimilars performance below expectations for Biocon : ICICI Direct

The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.

Industry-academia collaboration key to strengthening pharma R&D
News | March 04, 2021

Industry-academia collaboration key to strengthening pharma R&D

The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .

How a robust supply chain ensured Indian pharma industry’s triumph over COVID-19
Supply Chain | February 26, 2021

How a robust supply chain ensured Indian pharma industry’s triumph over COVID-19

The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges

Latest Stories

Fermenta receives CEP by EDQM for Vitadee 100 SD

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging